Data / Drug companies / Sanofi Vaccines US Inc.
Sanofi Vaccines US Inc.: 24 products in the FDA NDC directory, labeler code 49281
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Sanofi Vaccines US Inc. (labeler code 49281) lists 24 products in the FDA National Drug Code Directory, covering 6 finished drugs by generic name. By type: 21 vaccines, 3 prescription drugs. Its main marketing category is biologics (BLA). The newest product started marketing on August 27, 2026.
The request: Watch Sanofi Vaccines US Inc. (FDA labeler code 49281): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 49281
- Products in commercial distribution
- 24
- Packages
- 37
- Finished drugs by generic name
- 6
- Prescription products
- 3
- Over the counter products
- 0
- Flagged as original packager
- 3 of 3 products that carry the flag
- Started marketing in the last 12 months
- 6
- Products with a marketing end date set
- 7
- Earliest marketing start
- May 22, 1953
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Biologics (BLA) | 24 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Vaccines | 21 | 87.5% |
| Prescription drugs | 3 | 12.5% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Nirsevimab | 2 | 1 |
| Salmonella typhi ty2 vi polysaccharide antigen | 1 | 2 |
| Sodium chloride | 1 | 71 |
| Nvx-cov2928 | 1 | 1 |
| Tuberculin purified protein derivative | 1 | 3 |
| Yellow fever virus strain 17d-204 live antigen | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, suspension | 12 | 50% |
| Injection, solution | 4 | 16.7% |
| Injection | 4 | 16.7% |
| Kit | 3 | 12.5% |
| Injection, powder, lyophilized, for suspension | 1 | 4.2% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Inactivated Clostridium Tetani Vaccine | 4 |
| Inactivated Corynebacterium Diphtheriae Vaccine | 4 |
| Inactivated Bordetella Pertussis Vaccine | 3 |
| Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody | 2 |
| Inactivated Poliovirus Vaccine | 2 |
| Inactivated Salmonella Typhi Vaccine | 1 |
| Osmotic Laxative | 1 |
| Inactivated Meningococcal Vaccine | 1 |
| Skin Test Antigen | 1 |
| Tuberculosis Skin Test | 1 |
| Live Attenuated Yellow Fever Virus Vaccine | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Nuvaxovid 2026-27 | 49281-026 | Injection, suspension | Biologics (BLA) | August 27, 2026 |
| Flublok trivalent northern hemisphere | 49281-726 | Injection | Biologics (BLA) | July 2, 2026 |
| Fluzone high dose northern hemisphere | 49281-126 | Injection, suspension | Biologics (BLA) | July 2, 2026 |
| Fluzone tiv sh 2026 | 49281-626 | Injection, suspension | Biologics (BLA) | February 20, 2026 |
| Fluzone tiv sh 2026 | 49281-315 | Injection, suspension | Biologics (BLA) | February 20, 2026 |
| Fluzone hd tiv sh 2026 | 49281-016 | Injection, suspension | Biologics (BLA) | February 20, 2026 |
| Fluzone trivalent northern hemisphere | 49281-645 | Injection, suspension | Biologics (BLA) | July 2, 2025 |
| Fluzone trivalent northern hemisphere | 49281-426 | Injection, suspension | Biologics (BLA) | July 2, 2024 |
| Beyfortus | 49281-575 | Injection | Biologics (BLA) | July 18, 2023 |
| Beyfortus | 49281-574 | Injection | Biologics (BLA) | July 18, 2023 |
| MenQuadfi | 49281-590 | Injection, solution | Biologics (BLA) | April 23, 2020 |
| Imovax rabies | 49281-252 | Kit | Biologics (BLA) | October 25, 2019 |
| Quadracel | 49281-564 | Injection, suspension | Biologics (BLA) | March 24, 2015 |
| Tenivac | 49281-215 | Injection, suspension | Biologics (BLA) | December 8, 2010 |
| Pentacel | 49281-511 | Kit | Biologics (BLA) | June 20, 2008 |
| Adacel TDaP | 49281-400 | Injection, suspension | Biologics (BLA) | June 10, 2005 |
| Menactra | 49281-589 | Injection, solution | Biologics (BLA) | January 14, 2005 |
| Daptacel | 49281-286 | Injection, suspension | Biologics (BLA) | May 14, 2002 |
| Typhim Vi | 49281-790 | Injection, solution | Biologics (BLA) | November 28, 1994 |
| ActHIB | 49281-545 | Kit | Biologics (BLA) | March 30, 1993 |
| Ipol | 49281-860 | Injection, suspension | Biologics (BLA) | December 21, 1990 |
| Tubersol | 49281-752 | Injection, solution | Biologics (BLA) | August 15, 1956 |
| Yf-vax | 49281-915 | Injection, powder, lyophilized, for suspension | Biologics (BLA) | May 22, 1953 |
| Diluent | 49281-912 | Injection | Biologics (BLA) | May 22, 1953 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.